SCHEMBL486192

SCHEMBL486192

CCc1ccc(-c2cncc(N(C)C(=O)O)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 2/20 0.44
XDH P47989 1/20 0.44
EGLN1 Q9GZT9 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
CA12 O43570 1/20 0.40
ALPL P05186 1/20 0.40
CA9 Q16790 1/20 0.40
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RAB9A P51151 2/20 0.38
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 1/20 0.38
MKNK1 Q9BUB5 4/20 0.37
MKNK2 Q9HBH9 4/20 0.37
CYP11B2 P19099 1/20 0.37
S1PR1 P21453 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16579491 0.74 XDH (0.58) SLC22A12XDHEGLN1SMN1; SMN2MAPT
SCHEMBL31301426 0.73 SCN10A (0.47) SLC22A12XDHSMN1; SMN2MAPTHTT
SCHEMBL486190 0.71 HDAC1 (0.48) SLC22A12XDHEGLN1SMN1; SMN2MAPT
SCHEMBL641553 0.71 CYP11B1 (0.60) SLC22A12XDHSMN1; SMN2MAPTHTT
SCHEMBL24801835 0.70 CYP2A6 (0.49) SLC22A12XDHSMN1; SMN2MAPTHTT
SCHEMBL3713842 0.70 PI4KA (0.58)
SCHEMBL640338 0.70 CYP2C9 (0.59) XDHSMN1; SMN2MAPTHTTCCNC
SCHEMBL11240064 0.69 RXRA (0.43) CA12CA9RXRARXRBRAB9A
SCHEMBL485977 0.68 SMN1; SMN2 (0.57) SLC22A12XDHSMN1; SMN2MAPTHTT
SCHEMBL3507485 0.68 POLB (0.48) SMN1; SMN2MAPTHTTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411363-B1 SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS BAYER IP GMBH (DE) 2015-10-07 EP disclosed
US-20120046268-A1 Substituted piperidines as Par-1 Antagonists BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-02-23 US disclosed
EP-2411363-A1 SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS Bayer Pharma AG (DE) 2012-02-01 EP disclosed
WO-2010108608-A1 SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046268-A1 Substituted piperidines as Par-1 Antagonists F2R, F2RL1, F2RL3 SLC22A12 4503/4885XDH 2390/4885EGLN1 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.